Skip to main content
S&P 5007,818.93+0.58%DOW51,521.28+0.49%NASDAQ27,599.89+0.45%BTC$83,548.00-3.14%ETH$2,578.97-4.90%GOLD$4,148.70-0.92%OIL$89.85+0.46%
Smart Investors Daily
SID Premium
PL

NASDAQ · PLRZ

Polyrizon Ltd.

Healthcare · Biotechnology

$9.67

Up+$0.32 (+3.42%)

Updated Oct 7, 2026, 10:06 AM

SID Score

3.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
12.37M
P/E ratio
-19.02
Dividend yield
0.00%
52-week range
$2.88 – $18.20
Volume
6.25K
Avg. volume
3.19M

Price performance · PLRZ

PLRZ price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

PLRZ closed at $9.67 after 21 trading sessions, down 13.28% for the selected period.

Last close
$9.67
Period change
-13.28%
Period low
$9.26
Period high
$11.39
Daily close
View OHLC price history
PLRZ OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$9.50$9.6697$9.26$9.66976.25K
Oct 5, 2026$9.48$9.88$9.1289$9.2616.97K
Oct 2, 2026$10.56$10.87$9.15$9.6156.47K
Oct 1, 2026$10.30$10.475$10.1651$10.322.02K
Sep 30, 2026$10.39$10.87$10.0802$10.783113.53K
Sep 29, 2026$10.61$11.00$10.36$10.498.75K
Sep 28, 2026$10.50$10.76$10.36$10.364.47K
Sep 25, 2026$10.50$10.775$10.50$10.7751K
Sep 24, 2026$10.93$11.3499$10.50$10.5113.39K
Sep 23, 2026$10.62$11.99$10.0906$11.1640.06K
Sep 22, 2026$11.03$11.03$10.50$10.666.53K
Sep 21, 2026$11.00$11.00$10.55$10.9014.85K
Sep 18, 2026$11.01$11.0719$10.36$10.9932.06K
Sep 17, 2026$11.60$11.60$9.15$11.03159.44K
Sep 16, 2026$11.31$11.80$10.61$10.6512.07K
Sep 15, 2026$11.10$11.39$10.956$11.392.07K
Sep 14, 2026$10.99$11.525$10.625$11.3269.32K
Sep 11, 2026$11.19$11.355$10.495$11.0376.58K
Sep 10, 2026$10.65$11.28$10.42$11.2343.81K
Sep 9, 2026$11.25$11.25$10.32$10.7575.45K
Sep 8, 2026$11.08$11.85$10.99$11.15164.2K

Latest PLRZ news

The latest Smart Investors Daily articles mentioning PLRZ.

Stock researchCompany · Overview

PLRZ research

Overview

Company profile and research snapshot.

Company profile

Polyrizon Ltd is a clinical development stage biotech company specializing in the development of nasal gels to provide preventative treatment to protect against a wide cross-section of viruses, including certain variants of COVID-19 that are also considered to cause more infections and spread faster than the original strain of the virus (the CDC expects that additional variants of the virus will continue to occur), influenza, allergens, and other toxins. Its technology platforms are Capture & Contain and Trap & Target.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Aug 20, 2026

Polyrizon Completes Clinical Site Network for NASARIX™ Study and Advances Toward Patient Enrollment

Polyrizon completes contracting with all five U.S. clinical sites and advances its NASARIX™ study toward enrollment of 120 patients Raanana, Israel, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the “Company” or “Polyrizon”), a development-stage biotech company specializing in the development of innovative intranasal hydrogels, today announced that it has completed contracting with the fourth and fifth clinical sites participating in its clinical study of NASARIX™ Allergy Bloc

Yahoo · Feb 26, 2026

Polyrizon Announces Successful Study of its Naloxone Formulation Demonstrating Enhanced Nasal Deposition Profile Versus Commercial Reference Product

Raanana, Israel, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced results from a comparative study evaluating the regional nasal deposition profile of its naloxone formulation versus a commercial reference product. The study was conducted at the University of Parma’s Biopharmanet-TEC research center under the scientific supervision of Prof. Fabi

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By